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Abstract
Background: Diametrically opposed positions exist regarding the deleterious effects of elevated lactate. There are
data suggesting that it is a detrimental proxy for tissue hypoperfusion and anaerobic metabolism in sepsis and an
alternative viewpoint is that some of the hyperlactatemia produced maybe adaptive. This study was conducted to
explore the relationship between serum lactate levels, mean arterial blood pressure (MAP), and sympathetic stimulation in patients with sepsis.
Methods: Retrospective analysis of prospectively collected clinical data from four community-based hospitals and
one academic medical center. 8173 adults were included. Heart rate (HR) was used as a surrogate marker of sympathetic stimulation. HR, MAP, and lactate levels were measured upon presentation.
Results: MAP and HR interacted to affect lactate levels with the highest levels observed in patients with low MAP
and high HR (3.6 mmol/L) and the lowest in patients with high MAP and low HR (2.2 mmol/L). The overall mortality rate was 12.4%. Each 10 beats/min increase in HR increased the odds of death 6.0% (95% CI 2.6% to 9.4%), each
1 mmol/L increase in lactate increased the odds of death 20.8% (95% CI 17.4% to 24.2%), whereas each 10 mmHg
increase in MAP reduced the odds of death 12.3% (95% CI 9.2% to 15.4%). However, HR did not moderate or mediate
the association between lactate and death.
Conclusions: In septic patients, lactate production was associated with increased sympathetic activity (HR ≥ 90) and
hypotension (MAP < 65 mmHg) and was a significant predictor of mortality. Because HR, lactate, and MAP were associated with mortality, our data support the present strategy of using these measurements to gauge severity of illness
upon presentation. Since HR did not moderate or mediate the association between lactate and death, criticisms alleging that lactate caused by sympathetic stimulation is adaptive (i.e., less harmful) do not appear substantiated.
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Introduction
Although the incidence, associated morbidity, attributable mortality, and overall costs related to sepsis vary
widely, it is generally agreed that sepsis is ubiquitous
and adversely affects patients [1–4]. Early identification of sepsis and aggressive restoration of peripheral
perfusion are the cornerstones of management. To
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improve outcomes, sepsis bundles focusing on early
resuscitation and early antibiotics have been implemented. Serial measures of lactate—a byproduct of
anaerobic metabolism used as a surrogate marker for
suboptimal perfusion—are increasingly advocated as a
target of resuscitation in sepsis bundles. The 2016 Surviving Sepsis Campaign Guidelines endorse measuring
lactate levels within the first hour of resuscitation and
every two to four hours thereafter if the initial level
is > 2.0 mmol/L. [5]
Increased reliance on lactate levels to guide clinical
decision-making in sepsis is driven by studies associating elevated lactate with increased mortality in sepsis.
One retrospective study found that lactate levels greater
than 2.5 mmol/L correlated with a 28-day mortality of
16.9% [6]. The prognostic value of lactate was further
emphasized when lactate-directed resuscitation led to
lower Sequential Organ Failure Assessment (SOFA)
scores, earlier cessation of inotropes, earlier weaning
from mechanical ventilation, earlier intensive care unit
(ICU) discharge, and a 9.6% absolute reduction in hospital mortality when compared to usual care. [7] Rising levels of lactate are also associated with increasing
mortality, regardless of the presence/absence of shock.
[8] Taken collectively, these data suggest that elevated
lactate is a deleterious proxy for tissue hypoperfusion
and anaerobic metabolism in sepsis. However, there are
other etiologies for hyperlactatemia including reduced
clearance (i.e., liver dysfunction in the setting of hypoperfusion) and medication administration (i.e., large volumes of lactated Ringer’s solution, excessive albuterol)
[9–12].
An alternative viewpoint is that some of the hyperlactatemia produced during sepsis may be an adaptive
response. Sepsis-related increases in metabolic rate and
catecholamine levels increase glycolysis, glycogenolysis,
gluconeogenesis, and reduce insulin release. This cascade ultimately results in increased pyruvate production
with shunting to lactate production which can be used
as an alternate energy source. The net effect is increased
lactate production in the absence of tissue hypoxia—
a form of Type B2 lactic acidosis [13, 14]. This line of
thinking, espoused in several popular online blogs and
podcasts, suggests that because not all of the etiologies
for increased lactate seen are harmful, clinicians should
parse out adaptive lactate signaling an intact stress
response from lactate caused by hypoperfusion and cellular ischemia [15–17]. One clinical trial supports this
hypothesis as administration of esmolol—pharmacologic blunting of the catecholamine response—reduced
lactate concentrations in patients with septic shock
[18]. Another study showed that increasing serum lactate in the earliest phases of sepsis, presumably due to
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sympathetic activation, was associated with reduced
mortality [19].
Given these diametrically opposed positions regarding
the deleterious effects of elevated serum lactate, we conducted this retrospective study to explore whether elevations of lactate in septic patients were driven primarily by
abnormal blood pressure or by increased catecholamine
activity. Because catecholamine levels are not measured
directly during routine clinical care, we used patients’
presenting heart rates as a coarse proxy for their degree
of inherent sympathetic activity.

Materials and methods
Patients

After obtaining approval from Creighton University’s
Institutional Review board, we retrospectively reviewed
the charts of all hospital admissions between October 1,
2015, and June 30, 2018, that included an ICD-9/ICD10 code for sepsis. A Structured Query Language (SQL)
program was written to search for all patient visits in the
clinical documentation system and that their final coding
included a diagnosis code of sepsis, severe sepsis (with or
without septic shock). Enrolled patients were admitted to
any of the six Catholic Health Initiative hospitals in the
Omaha, Nebraska, metropolitan area. We included only
adult patients in this study: because the ages of majority
are 19 years in Nebraska and 18 years in Iowa, this inclusion criterion varied geographically. Of the 11,859 identified sepsis admissions, 3686 were excluded for missing
data or repeat sepsis admission, resulting in 8173 unique
patients for analysis (see Fig. 1).
Outcomes

The primary outcome was serum lactate level (in
mmol/L) measured on admission. Secondary outcomes
included in-hospital death and discharge from the intensive care unit (ICU).
Covariates

All data abstracted/analyzed—including heart rate (HR),
mean arterial blood pressure (MAP) and serum lactate—
were collected at the time of presentation to the hospital, prior to the administration of fluids antibiotics, and/
or vasopressors. When evaluating lactate level, MAP
and HR were considered primary covariates. In separate
analyses, we included MAP and HR as either continuous or dichotomous. When dichotomized, we used systemic inflammatory response syndrome (SIRS) criteria
to stratify patients as hypotensive (MAP < 65 mm Hg)
or normotensive (MAP ≥ 65 mm Hg) and as having low
sympathetic drive (HR < 90 beats per minute [bpm]) or
high sympathetic drive (HR ≥ 90 bpm). Secondary covariates included age, temperature, hepatic dysfunction on
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Fig. 1 Schematic showing excluded admissions

admission, history of heart failure, and diabetes. Age
and temperature were mean centered prior to analysis, and hepatic dysfunction was defined as bilirubin
concentration > 2 mg/dL.

Statistical analysis
Depending on data distribution, continuous variables are
presented as mean ± standard deviation or median and
interquartile range; categorical variables are presented
as frequency and percent alongside Agresti–Coull confidence intervals, when appropriate. Because serum lactate was severely positively skewed and heteroscedastic,
it was modeled using an identity link and log-normal
distribution of residuals. Two-way interaction effects
were estimated to determine whether HR moderated
the association between MAP and lactate. For categorical MAP and HR, all post hoc comparisons used the
Tukey–Kramer adjustment to control Type I error rates.
In-hospital death was modeled using logistic regression
models; we evaluated both the moderation and mediation of HR on the effect of lactate on in-hospital death
(see Additional file 1: Appendix for mediation analysis
plan). The probability of discharge from the ICU was
modeled using a Cox proportional-hazards model with

ICU LOS censored upon patient death or at day 28. For
all outcomes, the functional form of continuous predictors was assessed using Loess methods with nonlinearity modeled using piecewise linear effects as appropriate.
The proportionality of hazards assumption was evaluated
statistically via interactions with time. All regressiontype models included fixed facility indicator variables
to account for the clustering of patients within a facility.
SAS v. 9.4 was used for all statistical analysis with p < 0.05
used to indicate statistical significance.

Results
Table 1 summarizes the study participants’ demographic
and clinical characteristics.
Serum lactate level

After adjusting for covariates, a statistically significant
two-way interaction effect between categorical MAP
and HR (interaction p = 0.004) was seen indicating that
the lactate level for a given MAP category was different
between the HR categories (Table 2). The highest lactate level was observed in patients with low MAP/high
HR, whereas the lowest lactate level was observed in
patients with high MAP/low HR. Lactate levels by group
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Table 1 Patient demographic and clinical characteristics
(N = 8173)
Variable

Value

Male, n (%)

4062 (49.7)

Age, years, mdn [IQR]

67 [55–79]

BMI, kg/m2, mdn [IQR]

27.9 [23.5–33.9]

Lactate, mmol/L, mdn [IQR]

2.0 [1.3–2.9]

Heart rate, bpm, mean ± SD

100.4 ± 22.7

≤ 90, n (%)

2736 (33.5)

> 90, n (%)

5437 (66.5)

MAP, mm Hg, mean ± SD

93.2 ± 21.2

< 65, n (%)

709 (8.6)

≥ 65, n (%)

7470 (91.4)

Systolic

133.0 ± 30.5

Blood pressure, mmHg, mean ± SD
Diastolic

73.3 ± 19.1

Bilirubin, mg/dL, mdn [IQR]

0.6 [0.4–1.0]

≤ 2, n (%)

7560 (92.5)

In our cohort, the effect of continuous MAP and HR
each had a piecewise linear association with lactate levels. Specifically, after adjusting for covariates, lactate
level was 8.9% lower per 10 mmHg higher MAP until a
MAP of 90 mmHg (95% CI 7.6% to 10.1%, p < 0.001), after
which lactate was 1.9% higher per 10 mmHg higher MAP
(95% CI 0.8% to 2.9%, p < 0.001). By contrast, after adjusting for covariates, lactate level was non-significantly
1.2% higher per 10-bpm higher HR until 95 bpm (95%
CI 0.2% lower to 2.5% higher, p = 0.096), after which lactate increased 8.6% for every 10-bpm higher HR (95% CI
7.6% to 9.6%, p < 0.001). In the final model that combined
the piecewise effects of MAP and HR, after adjusting for
facility, statistically significant two-way interactions were
indicated between MAP and HR (Fig. 2: see Additional
file 2: Table S1 for full model results), such that the attenuating effect of higher MAP on lactate level was larger in
patients with higher HR.

613 (7.5)

In‑hospital death

Platelets, 109/L, mdn [IQR]

219 [161–287]

Creatinine, mg/dL, mdn [IQR]

1.2 [0.9–1.8]

Temperature, °C, mdn [IQR]

36.9 [36.5–37.6]

History of heart failure, n (%)

1976 (24.2)

Diabetes, n (%)

2909 (35.6)

ICU LOS, days, mdn [IQR]

4 [2–7]

Hospital LOS, days, mdn [IQR]

5 [3–8]

Glasgow Coma Score, mdn [IQR]

15 [14,15]

The overall in-hospital mortality rate for this cohort was
12.4% (95% CI 11.7% to 13.1%). As shown in Table 3, after
adjusting for the covariates, every 1 mmol/L increase in
lactate was associated with 20.8% higher odds of death
(95% CI 17.4% to 24.2%, p < 0.001) and 10 bpm higher
HR was associated with 6.0% higher odds of death (95%
CI 2.6% to 9.4%, p < 0.001). By contrast, every 10 mmHg
higher MAP was associated with 12.3% lower odds of
death (95% CI 9.2% to 15.4%, p < 0.001). When evaluating whether HR moderated the odds of in-hospital death
for higher lactate or MAP, the two-way interactions were
not statistically significant (lactate-by-HR p = 0.082;
MAP-by-HR p = 0.393) indicating that the odds of death
reported above for lactate and MAP were constant irrespective of a patient’s HR. Further, HR did not mediate
the association between lactate and death (see Additional
file 1: Appendix for full results): although patients with
higher HR had clinically higher lactate levels as reported
above, patients with higher lactate levels did not have
clinically higher HR (1 mmol/L higher lactate was associated with 1.8 bpm higher HR) which limited the ability of
HR to mediate the association between lactate and death.

> 2, n (%)

Discharge disposition, n (%)
Died

1041 (12.1)

Home

4368 (50.9)

Home healthcare

569 (6.6)

Long-term care

195 (2.3)

Skilled nursing

1736 (20.2)

Rehab facility

180 (2.1)

Other

496 (5.8)

Table 2 Adjusted model-estimated serum lactate levels
by MAP and heart rate
Heart rate

< 65 mm Hg

≥ 65 mm Hg

n

mean [95% CI]

n

mean [95% CI]

324

2.7 [2.5–2.9]

2412

2.2 [2.1–2.2]

379

3.6 [3.4–3.8]

5058

2.6 [2.5–2.6]

Mean arterial pressure
≤ 90 bpm
> 90 bpm

were statistically different from each other (each Tukey–
Kramer adjusted p < 0.001) except for high HR/high
MAP vs. low HR/low MAP (Tukey–Kramer adjusted
p = 0.680).

Probability of ICU discharge

A total of 5145 (63.0%) patients spent time in the
ICU during their hospital stay, of whom 4335 (84.3%)
were discharged alive. After adjustment for covariates, 1 mmol/L higher lactate was associated with
4.0% lower likelihood of ICU discharge (95% CI 2.5%
to 5.4%, p < 0.001), 10 mmHg higher MAP was associated with 1.7% higher likelihood of ICU discharge
(95% CI 0.4% to 3.1%, p = 0.014), and 10 bpm higher
HR was associated with a non-statistically significant
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Fig. 2 Model-estimated serum lactate level by mean arterial pressure and heart rate. Error bars represent 95% confidence intervals

0.9% decreased likelihood of ICU discharge (95% CI
2.2% decrease to 0.5% increase, p = 0.203). We evaluated whether HR moderated the likelihood of ICU
discharge for higher lactate or MAP. Although the lactate-by-HR interaction was not statistically significant
(interaction p = 0.793; indicating that the effect of lactate was constant irrespective of HR), the association
between MAP and ICU discharge was moderated by
HR (interaction p = 0.023) such that higher MAP was
associated with a higher likelihood of ICU discharge
only in patients with HR at or above 97 bpm (Additional file 3: Figure S1).
Sensitivity analyses: single admissions and the ICU cohort

Of the 8173 patients in our sample, 1506 (18.4%) had
more than one hospital admission during the study
period that included a sepsis diagnosis, for whom
the median number of admissions was 2 [IQR: 2–3].
We expected that multiple sepsis admissions would
be a proxy for severity; however, the mortality rate in
patients with repeated admissions was 0.3% (vs. 15.2%
in patients with only one admission; p < 0.001). We
repeated all analyses excluding these patients and the
results were nearly identical, albeit with slightly wider
confidence intervals given the reduction in sample size.
Finally, restricting the analysis to only the 5145 patients
with an ICU admission resulted in replication of the
pattern of results reported above for the overall cohort.

Discussion
Lactate kinetics are multifaceted and often over-simplified in critical illness. An ongoing challenge to the primacy of lactate in sepsis has been the assertion that some
degree of hyperlactatemia in septic patients results from
catecholamine stimulation of ß2 receptors and that the
resulting lactate (so-called Type B lactic acidosis) confounds the predictive utility of lactate in sepsis. Accordingly, our study attempted to explore this issue using
data from a large cohort of sepsis patients and a relatively
simplistic design. Our intent was to assess whether the
effects of elevated lactate level in septic patients were
affected by varying levels of systemic catecholamine activation (evidenced by higher presenting HR). Although
our results support the hypothesis that patients with
higher levels of sympathetic activity have higher levels
of lactate, mortality was directly linked to elevations in
lactate and was not affected by the degree of sympathetic
activity.
Using accepted cut-points from the SIRS criteria for MAP and HR, we categorized septic patients
as normotensive (MAP ≥ 65 mm Hg) or hypotensive
(MAP < 65 mm Hg) and as having low sympathetic drive
(HR < 90 bpm) or high sympathetic drive (HR ≥ 90 bpm).
This allowed us to put septic patients into four groups:
(1) hypotensive with low sympathetic drive; (2) hypotensive with high sympathetic drive; (3) normotensive with low sympathetic drive; and (4) normotensive
with high sympathetic drive. Our hypothesis was that if
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Table 3 Results for in-hospital death and time-to-ICU discharge
Variable

Unadjusted
OR [95% CI]

Adjusted
p

OR [95% CI]

Wald

p

In-hospital death
Age (0 = 67; per 10 years)

1.46 [1.40–1.53]

< 0.001

1.55 [1.47–1.63]

271.41

< 0.001

0.86 [0.83–0.89]

< 0.001

0.90 [0.86–0.93]

32.35

< 0.001

Bilirubin > 2 mg/dL

2.70 [2.22–3.28]

< 0.001

2.33 [1.88–2.90]

58.21

History of heart failure

1.23 [1.06–1.43]

0.006

1.01 [0.86–1.19]

0.02

Temperature (0 = 98.4)

< 0.001
0.889

Diabetes

0.63 [0.55–0.73]

< 0.001

0.65 [0.56–0.76]

28.68

< 0.001

Lactate (per 1 mmol/L)

1.26 [1.23–1.29]

< 0.001

1.21 [1.17–1.24]

171.84

< 0.001

MAP (per 10 mmHg)

0.83 [0.80–0.85]

< 0.001

0.88 [0.85–0.91]

54.45

< 0.001

0.87 [0.82–0.93]

< 0.001

–

–

–

1.07 [1.02–1.12]

0.005

–

–

–

–

0.058

Heart rate (per 10 bpm)a
≤ 95 bpm

> 95 bpm

Slope difference

–

< 0.001

Overall

–

–

Variable

Unadjusted
HR [95% CI]

–
1.06 [1.03–1.09]

12.31

< 0.001

Adjusted
p

HR [95% CI]

Wald

p

Discharge from the ICU
Age (0 = 67; per 10 years)

Temperature (0 = 98.4)

0.95 [0.93–0.97]

< 0.001

0.95 [0.93–0.97]

27.70

< 0.001

1.07 [1.06–1.09]

< 0.001

1.06 [1.05–1.08]

58.95

< 0.001

Bilirubin > 2 mg/dL

0.65 [0.58–0.73]

< 0.001

0.70 [0.62–0.79]

35.30

< 0.001

History of heart failure

0.88 [0.82–0.94]

< 0.001

0.88 [0.82–0.95]

12.20

< 0.001

Diabetes

1.11 [1.04–1.18]

0.001

1.10 [1.03–1.17]

8.89

Lactate (per 1 mmol/L)

0.95 [0.93–0.96]

< 0.001

0.96 [0.95–0.98]

28.12

0.003

MAP (per 10 mmHg)

1.03 [1.01–1.04]

< 0.001

1.02 [1.01–1.03]

6.04

0.014

Heart rate (per 10 bpm)

1.01 [1.00–1.03]

0.024

0.99 [0.98–0.01]

1.62

0.203

< 0.001

Both the unadjusted and adjusted models included facility indicator variables as fixed effects to account for the clustering of patients within facilities.
a

After adjusting for covariates, the slope difference in the log-odds of in-hospital death before vs. after HR of 95 was no longer statistically significant (p = 0.058); as
such, the adjusted model includes a single overall effect of HR
OR odds ratio, HR hazard ratio, MAP mean arterial pressure

both hypotension and sympathetic independently drive
increased lactate levels, patients with both hypotension and high sympathetic drive would have the highest
lactate levels, patients with hypotension or high sympathetic drive alone would have intermediate lactate levels,
and patients with neither hypotension nor high sympathetic drive would have the lowest lactate levels. Our data
precisely showed this relationship. Further, when holding
MAP constant, we found that patients presenting with
higher HR consistently had higher lactate levels compared to patients with lower HR (Fig. 2). These findings
suggest that intrinsic sympathetic activity drive increases
lactate levels. This relationship between HR and lactate
was not affected by age, temperature, hepatic dysfunction, heart failure, and/or diabetes: when these factors
were considered as covariates in statistical models, all
inferences and the observed magnitude of the effects
seen did not change.

Conventional wisdom regarding sepsis has focused
on elevated lactate as a fundamental marker of tissue
hypoxia due to distributive and/or hypovolemic shock.
This has led to multiple disproven therapeutic recommendations including blood transfusions to maintain
the hemoglobin > 10 mg/dL and using inotropes to drive
the mixed venous oxygen saturation to > 70% among others. It is increasingly understood that in septic patients,
excess lactate production through multiple avenues and
reduced lactate clearance likely come into play—and that
lactate production does not always signal physiologic
aberrancy due to dysoxia [20–23].
However, any incremental lactate elevations due to
increased catecholamines remained associated with
an increased risk of death and were not less harmful as
some have postulated. Consistent with numerous other
studies, lactate was the strongest predictor of in-hospital
death in this cohort of septic patients. Because we did
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not find a statistically significant interaction between HR
and either lactate or MAP when looking at mortality or
ICU discharge, our data do not suggest that increased HR
(sympathetic drive) is protective. This is not entirely surprising and one could posit that our analysis is another
example of the ‘squeezing the balloon’ analogy: any
reduction in lactate production caused by an increase in
MAP is replaced by a comparable amount of lactate due
to the increased catecholamines needed to increase the
HR to improve the MAP. Another alternate explanation
suggests that lactate etiology (aerobic or anaerobic) is
irrelevant and that lactate is a marker of a more severely
dysregulated inflammatory response—a known maladaptive response [24]. Regardless, each of these hypotheses
is consistent with the observation that elevated lactate
levels are ominous even in the absence of shock [8]. Our
study lends external validity to this association between
lactate and mortality.
Our study supports the concept that hyperlactatemia
in sepsis is more complex than simple anaerobic metabolism and that catecholamine stimulation can affect both
MAP and lactate levels. One could propose that because
lactate is not solely a marker of tissue hypoperfusion,
intensivists should take pause in using lactate in isolation
to guide resuscitation—an idea supported by a recent
large, randomized, controlled trial which did not show
benefit to using lactate kinetics to guide resuscitation.
[25] As suggested by others, this subject deserves significant further study given the magnitude of the problem
posed by septic shock coupled with the trend whereby
lactate levels have evolved into a quality metric. [26]
However, our finding that mortality was associated with
increased lactate—and the lack of moderation/mediation of this relationship by HR—lactate appears to be an
appropriate marker of severity of illness without consideration of the degree of sympathetic activity.
The biggest strengths of our study are the large sample size and the use of data from multiple hospitals, the
majority of which were community-based. To maximize
standardization despite using a retrospective dataset, all
abstracted variables were objective measurements made
at the time of admission. Because baseline clinical data
and labs were used for analysis, we obviated the potential confounding effects of the most clinically important
medications (i.e., beta-adrenergic agonists or blockers, sedatives) and other therapeutic interventions (i.e.,
mechanical ventilation) that could affect heart rate. We
were also purposeful in including all patients with sepsis—not just those admitted to the ICU—as current sepsis alerts, treatment guidelines and/or quality metrics
often include these individuals.
However, our study is not without significant limitations that must be considered when interpreting our
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results. The biggest barrier to drawing definitive conclusions from this study is our use of the HR as a surrogate
for sympathetic activity as opposed to directly measuring catecholamine levels. Admittedly, HR is a very
coarse measure of sympathetic activity and is potentially
affected by multiple other factors including degree of
fluid resuscitation, stroke volume, exogenous catecholamines, tachyarrhythmias, home medications (beta blockers, amiodarone, midodrine), fever, and comorbid illness
(chronic hypertension). However, HR is uniformly available in real-time and is routinely used by clinicians at the
bedside as a surrogate marker for sympathetic activation. Although we could effectively minimize the effects
of some of these variables (fluid resuscitation, exogenous
catecholamines) by collecting data at presentation prior
to any therapy, other variables (tachyarrhythmia, comorbidity) could not be accounted for.
Another limitation was our reliance upon MAP as the
sole marker of perfusion. We used MAP as our index of
perfusion as it is a key component of the Surviving Sepsis Campaign and the ESICM guidelines. However, MAP
does not consistently correlate with tissue perfusion at
the microcirculatory level [27]. Other markers of tissue
perfusion such as urine output, capillary refill, and central venous oxygen saturation were not reliably available
across facilities. In addition to the biases inherent with
a retrospective study design (selection bias, measurement error, confounding), we did not adjust for severity of illness via acuity scores (e.g., APACHE, SOFA) for
two reasons: (1) APACHE score subsumes MAP and HR
which precluded evaluation of the primary independent
variables in this study and (2) acuity scores were not calculated for most patients cared for in the four community-based hospitals.
A definitive resolution of this issue would ultimately
require further investigation—ideally prospective data
with direct measurement of serum catecholamines, an
assessment of presenting severity of illness, delineation
of concurrent medications, and controlling for medical comorbidities. However, such an extensive endeavor
should only be undertaken if we suspect that the effort
might meaningfully alter clinical practice. Although
imperfect, our data do not suggest any effect of sympathetic activity on the association between lactate and
mortality. Accordingly, efforts to delineate this issue further do not appear justified.

Conclusion
In this retrospective study, higher HR (used as a marker
of sympathetic stimulation) was associated with higher
lactate levels irrespective of MAP in septic patients.
However, HR was not associated with either mortality or the likelihood of ICU discharge and lactate level
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was the most significant predictor of untoward outcomes. Because efforts to reverse hypotension in septic patients may simultaneously affect HR, the ultimate
effects on lactate are complicated and potentially unpredictable. However, the strong association between lactate and mortality was not moderated or mediated by
sympathetic activity. As such, lactate level is clearly a
marker of severity of illness and mortality—whether it
appears to be driven by hypotension or by sympathetic
stimulation.
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